The therapeutic potential of targeting RNA

靶向RNA的治疗潜力

• 批准号: G0802629/1
• 负责人: David Brook
• 金额: $ 11.09万
• 依托单位: University of Nottingham
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2009
• 资助国家: 英国
• 起止时间: 2009 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0802629%2F1
• 关键词: therapeutic; potential; targeting; RNA

Myotonic Dystrophy (DM) is the most common form of muscular dystrophy in adults. Symptoms include muscle weakness and wasting, cataracts, diabetes, and irregular heartbeat. DM is an inherited condition that exists in two forms: DM1 and DM2. Both are caused by a different piece of faulty DNA. Recent experiments point to a common mechanism underlying both forms of DM. In both forms of DM the faulty DNA is made into RNA but this gets stuck in the nucleus and can be seen down the microscope as spots in the cells of DM patients. We have shown that three particular proteins, called muscleblind proteins, are present in the spots in DM cells. We aim to develop methods to study the faulty RNA, which will allow the development of assays or tests for drugs to treat the disorder. It is possible that the methods developed here may be applied to other human disorders.

强直性肌营养不良症（DM）是成人肌营养不良症中最常见的形式。症状包括肌肉无力和消瘦、白内障、糖尿病和心律不齐。DM是一种遗传性疾病，有两种形式：DM 1和DM 2。两者都是由不同的错误DNA片段引起的。最近的实验指出了两种形式DM的共同机制。在这两种形式的DM中，有缺陷的DNA被转化为RNA，但RNA被卡在细胞核中，在显微镜下可以看到DM患者细胞中的斑点。我们已经证明了三种特殊的蛋白质，称为肌盲蛋白，存在于DM细胞的斑点中。我们的目标是开发研究缺陷RNA的方法，这将允许开发治疗这种疾病的药物的测定或测试。这里开发的方法可能适用于其他人类疾病。